ArticleCost effectiveness and resource allocation : C/E2024

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.

Zahra Goudarzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.